ClinicalTrials.gg
CompletedNCT02172573Updated Jun 24, 2014

Safety and Efficacy of Pramipexole and Bromocriptine Combined With L-dopa in Parkinson's Disease

A Phase 3 interventional study of Pramipexole and Bromocriptine in Parkinson Disease, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2014-06-24.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
315
Allocation
Randomized
Ages
20 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 26 studies testing pramipexole in Parkinson Disease — none open to participants now, none under way, none of them phase 3. Pramipexole · Parkinson Disease.

Enrollment
9th of 26
315 · median 224
Started
1999
the only one that year
Phase 3
11 of 26
none open now
Registered
20th of 26
by date
Lead sponsor
16 of 26
Boehringer Ingelheim

Among the 26 studies testing pramipexole in Parkinson Disease, this one is the 9th largest by enrollment, is the only one that started in 1999, is one of 11 in phase 3, and was the 20th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

None of the 26 studies testing pramipexole in Parkinson Disease is open now. The open studies under Parkinson Disease, anywhere →

About pramipexole

Pramipexole: first FDA approval 1997 (MIRAPEX), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 20 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 26 studies testing pramipexole in Parkinson Disease as a file.
02

Study summary

The objective of the study was to evaluate the efficacy and safety of SND 919 (pramipexole) tablets administered in combination with L-dopa in patients with Parkinson's disease using placebo and bromocriptine tablets as comparators in a double-blind design (phase III comparative study).

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
20 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a diagnosis of Parkinson's disease (including juvenile parkinsonism)
  • Patients who meet all of the following inclusion criteria

    • Patients who were at least 20 years of age
    • In- or outpatients of either sex
    • Patients in any stage on the modified Hoehn and Yahr scale
  • Patients being treated with L-dopa who have any of the following clinical conditions and problems

    • Patients with the wearing-off phenomenon
    • Patients with the on-off phenomenon
    • Patients to whom a sufficient amount of L-dopa cannot be administered owing to the occurrence of an adverse event
    • Patients in whom the effect of L-dopa is attenuated
    • Patients in whom a dose increase of L-dopa has been refrained
    • Patients with freezing phenomenon

Exclusion criteria

Exclusion Criteria:

  • Patients being treated with other dopamine agonists (bromocriptine, pergolide mesylate, talipexole hydrochloride). Patients who have been treated with other dopamine agonist for at least 4 weeks before the start of the study (the day of giving ) are eligible for the study
  • Patients with a history of to ergot preparations
  • Patients with psychiatric symptoms such as confusion, hallucination, delusion, excitement, delirium, and abnormal behaviour
  • Patients with subjective symptoms derived from orthostatic hypotension
  • Patients with hypotension (systolic blood pressure less than 100 mmHg)
  • Patients wiht Raynaud disease
  • Patients with peptic ulcer
  • Patients with complications such as severe cardiac, renal, hepatic disease etc.
  • Patients with a current or past history of epilepsy
  • Women who are or may be pregnant and lactating women
  • Patients who are receiving any other products or who have received any other investigational product within 6 months of the study
  • Patients who are incompetent to give consent
  • Others judged by the investigator or co-investigator to be ineligible as subjects
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
315 participants (actual)

Study arms

  • Experimental
    Pramipexole

    Drug: Pramipexole

  • Experimental
    Bromocriptine

    Drug: Bromocriptine

  • Placebo comparator
    Placebo

    Drug: Placebo pramipexole · Drug: Placebo bromocriptine

Interventions

06

What researchers measure

Primary outcomes

  1. Change from baseline in total score of the Unified Parkinson's Disease Rating Scale (UPDRS) Part II (Activities of Daily Living)

    Time frame: Baseline and week 12

  2. Change from baseline in total score of UPDRS Part III (Motor Examination)

    Time frame: Baseline and week 12

Secondary outcomes

  1. Changes from baseline in sores of individual items on UPDRS Part II

    Time frame: Baseline and weeks 2, 4, 6, 8, 10, 12

  2. Changes from baseline in scores of individual items on UPDRS Part III

    Time frame: Baseline and weeks 2, 4, 6, 8, 10, 12

  3. Change from baseline in area under the curve (AUC) in the UPDRS Part II score

    Time frame: Baseline and weeks 2, 4, 6, 8, 10, 12

  4. Change from baseline in area under the curve (AUC) in the UPDRS Part III score

    Time frame: Baseline and weeks 2, 4, 6, 8, 10, 12

  5. Change from baseline in total score of UPDRS Part I (mentation, behaviour and mood)

    Time frame: Baseline and weeks 2, 4, 6, 8, 10, 12

  6. Change from baseline in total score of UPDRS Part IV (complications of therapy)

    Time frame: Baseline and weeks 2, 4, 6, 8, 10, 12

  7. Change from baseline in total score of UPDRS Part I-III

    Time frame: Baseline and weeks 2, 4, 6, 8, 10, 12

  8. Change from baseline in total score of UPDRS Part I-IV

    Time frame: Baseline and weeks 2, 4, 6, 8, 10, 12

  9. Change from baseline in Modified Hoehn & Yahr stage

    Time frame: Baseline and weeks 2, 4, 6, 8, 10, 12

  10. Clinical global impression of efficacy

    Time frame: week 12

  11. Number of patients with adverse events

    Time frame: up to 16 weeks

  12. Number of patients with clinically significant changes in vital signs (blood pressure, pulse rate)

    Time frame: up to 12 weeks

  13. Number of patients with abnormal changes in laboratory parameters

    Time frame: up to 12 weeks

  14. Number of patients with abnormal changes in 12-lead electrocardiogram (ECG)

    Time frame: up to 12 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 1999 and a primary completion of Jul 2000. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 20, 2014
First posted
Jun 24, 2014
Start
Apr 1999
Primary completionActual
Jul 2000
Last update
Jun 24, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02172573
Responsible party
Sponsor
First posted
Jun 24, 2014
Start date
Apr 1999
Primary completion
Jul 2000
Last update
Jun 24, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pramipexole · Bromocriptine

Start the discussion